April 16–18, Cotonou, Benin The « 3rd Journées Béninoises de Dermato-Vénérologie », held from April 16–18 in Cotonou under the auspices of the Ministry of Health of the Republic of Benin, was more than just a national dermatology conference. In a country with only about two dozen dermatologists serving a population of 13 million, Benin […]
Read More
The WHO EML Secretariat invites interested stakeholders to submit comments on the A-30 application. The deadline for submission of comments is Friday 18 April 2025, 18h00 CEST (Zürich time). ➜ Comments should be provided by via email to emlsecretariat@who.int in PDF format and must clearly reference the application A-30. ➜ Comments received will be published on […]
Read More
Highlights from the WHO Global Meeting on skin NTDs The much-anticipated Second WHO Global Meeting on Skin NTDs, held from March 24-26, 2025, at WHO headquarters in Geneva, provided a crucial platform to assess the progress made since the launch of the Strategic Framework for Skin NTDs in June 2022. This framework sets ambitious goals […]
Read More
Crusted Scabies and Dupilumab: A Case from Brazil➜ DOI: 10.25259/IJDVL_753_2024Crusted scabies is typically seen only in immunocompromised patients. This case from Brazil underscores the need for heightened vigilance in atopic dermatitis (AD) patients undergoing dupilumab treatment, particularly if they experience a sudden worsening of pruritus or lesions. More broadly, it highlights the risk of parasitic infections [...] Read More
Towards a Better Definition of Therapeutic Concepts in Atopic Dermatitis: Learning from Rheumatoid Arthritis Dear Colleagues, Dear Friends, Since the 1980s, rheumatoid arthritis (RA) has served as a model for therapeutic strategies in chronic inflammatory diseases. RA activity is assessed using multiple measures, including swollen joint counts, inflammatory markers, and radiographic signs of joint damage. […]
Read More
Defining a good indication of nemoluzimab based on clinical criteria➜ DOI: 10.1111/1346-8138.17626Nemolizumab is an effective treatment for pruritus in atopic dermatitis, but it has a relatively high incidence of cutaneous adverse events (cAEs). To optimize the use of nemolizumab, Japanese researchers investigated the relationship between baseline severity in specific body areas and the frequency of cAEs. [...] Read More
AI in AD and Allergy Research: Enhancing Collaboration with AI Experts Dear Colleagues, Dear Friends, Advances in AI over the past two years have significantly transformed the medical landscape, challenging vigorously our professional environment. A thorough review by Lisik et al. [link] provides an insightful overview of AI’s applications in AD and allergy research—a field […]
Read More
Season of birth shapes human milk microbiome➜ DOI: 10.1111/all.16469In this Australian study, the season of infant birth emerged as the strongest determinant of the microbiome community structure with impacts on five of the most abundant taxa. This seasonal effect is not correlated with a bad taxon more prevalent in winter where AD is more common. The [...] Read More
Communication from GADA Kicking off the new year with exciting news! We’re thrilled to announce the upcoming launch of the ISAD-GADA Fellowship! This program is designed to support #earlycareer #dermatologists or researchers in #epidemiology and #publichealth, providing them with the opportunity to collaborate with the GADA team, acquire valuable skills, and lead a small GADA […]
Read More
#event #free #online Save the date: April 4th, 2025 15:00-17:00 CEST Misinformation has been recognized as a critical Global Health challenge during the COVID pandemic, prompting its inclusion on the World Health Organization’s (WHO) priority list. In the digital age, the rapid spread of health-related misinformation on social media poses a significant threat to public […]
Read More